Loading news...
Shares of bioMerieux (OTCMKTS:BMXMF - Get Free Report) gapped up prior to trading on Friday. The stock had previously closed at $109.61, but opened at $115.00. bioMerieux shares last traded at $115.00, with a volume of 1,012 shares trading hands. Analysts Set New Price Targets Separately, BNP Paribas Exane cut shares of bioMerieux to
bioMérieux S.A. (BMXXY) Q4 2025 Earnings Call Transcript
bioMerieux (OTCMKTS:BMXMF - Get Free Report) saw unusually-high trading volume on Friday. Approximately 137 shares were traded during mid-day trading, an increase of 37% from the previous session's volume of 100 shares.The stock last traded at $110.00 and had previously closed at $112.57. Analyst Upgrades and Downgrades Separately, BNP Paribas Exane cut shares of
bioMérieux S.A. (OTCPK:BMXXY) Analyst/Investor Day November 4, 2025 8:30 AM EST Company Participants Aymeric Fichet Pierre Boulud - Chief Executive Officer Guillaume Bouhours - Executive VP of Purchasing and Information Systems & CFO Conference Call Participants Odysseas Manesiotis - BNP Paribas, Research Division Anchal Verma - JPMorgan Chase & Co, Research Division Aisyah Noor - Morgan Stanley, Research Division Dylan van Haaften - Stifel, Nicolaus & Company, Incorporated, Research Division Jan Koch - Deutsche Bank AG, Research Division Natalia Webster - RBC Capital Markets, Research Division Kavya Deshpande - UBS Investment Bank, Research Division Presentation Operator Welcome to the bioMérieux 2025 Third Quarter Sales Conference Call.
bioMérieux S.A. (OTCPK:BMXMF) Q4 2024 Results Conference Call March 7, 2025 8:00 AM ET Company Participants Aymeric Fichet - Investor Relations Pierre Boulud - Chief Executive Officer Guillaume Bouhours - Chief Financial Officer Conference Call Participants Aisyah Noor - Morgan Stanley Odysseas Manesiotis - BNP Paribas Marianne Bulot - Bank of America Maja Pataki - Kepler Natalia Webster - RBC Ed Hall - Stifel Jan Koch - Deutsche Bank Kavya Deshpande - UBS Operator Good day, and welcome to the bioMérieux Fourth Quarter Sales and Full Year 2024 Results Conference Call.
bioMérieux S.A. (OTCPK:BMXMF) Q2 2024 Results Conference Call September 5, 2024 8:00 AM ET Company Participants Aymeric Fichet - IR Pierre Boulud - Chief Executive Officer Guillaume Bouhours - CFO Conference Call Participants Hugo Solvet - Exane BNP Paribas Maja Pataki - Kepler-Chevreux Aisyah Noor - Morgan Stanley Kavya Deshpande - UBS Jan Koch - Deutsche Bank Marianne Bulot - Bank of America Operator Good day, and welcome to the H1 2024 Results Conference Call.
bioMérieux S.A. (BMXMF) CEO Alexandre Mérieux on Q4 2021 Results - Earnings Call Transcript
bioMérieux S.A. (BMXMF) CEO Alexandre Mérieux on Q3 2021 Results - Earnings Call Transcript
bioMérieux: Pioneering In Vitro Diagnostics
bioMérieux S.A. (BMXMF) CEO Alexandre Mérieux on Q4 2020 Results - Earnings Call Transcript
The COVID-19 crisis has drastically transformed the fortune of the medical services industry. The industry has been witnessingsignificant demand for telemedicine-focused online medical services.